共 838 条
[51]
Boguniewicz M(2016)Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis BMC Pediatr 2016 1675-2667
[52]
Boyle J(2019)Tolerability of topical treatments for atopic dermatitis Dermatol Ther (Heidelb). 9 71-358
[53]
Fonacier L(2018)Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement Br J Dermatol 178 768-558
[54]
Gelfand JM(2021)Current perspectives on the systemic management of atopic dermatitis J Asthma Allergy. 2021 14595-326
[55]
Grayson MH(2016)Two phase 3 trials of dupilumab versus placebo in atopic dermatitis N Engl J Med 375 2335-1883
[56]
Margolis DJ(2019)Management recommendations for dupilumab partial and non-durable responders in atopic dermatitis Am J Clin Dermatol 20 565-1442
[57]
Mitchell L(2022)Real-world effectiveness of newly initiated systemic therapy for atopic dermatitis in the United States: a claims database analysis Adv Ther 39 4157-159
[58]
Silverberg JI(2020)Dupilumab for the treatment of atopic dermatitis in an Austrian cohort-real-life data shows rosacea-like folliculitis J Clin Med 9 4-620
[59]
Schwartz L(2021)Dupilumab-induced psoriasis and alopecia areata: case report and review of the literature Ann Dermatol Venereol 148 198-6517
[60]
Simpson EL(2022)Dupilumab-induced psoriasis in a patient with atopic dermatitis and alopecia totalis: A case report and literature review Dermatol Ther 35 e15255-3050